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Abstract
Introduction: Two new microbicide products based on topical (vaginal) application of antiretroviral drugs  1% tenofovir gel and
the dapivirine ring  are currently in late-stage clinical testing, and results on their safety and effectiveness are expected to
become available in early 2015. WHO guidelines on the use of topical pre-exposure prophylaxis (topical PrEP) are important in
order to ensure that these new prevention products are optimally used.
Discussion: Given that these new topical PrEP products are designed to be woman initiated and will likely be delivered in
reproductive health settings, it is important to ensure that the guidance be framed in the context of comprehensive sexual and
reproductive health and human rights. In addition to the safety and effectiveness data resulting from clinical trials, and the
regulatory approval required for new products, the WHO normative guidelines on the use of topical PrEP will be essential for
rapid roll-out in countries.
Conclusions: Human rights standards and principles provide a framework for the provision of woman-initiated HIV prevention
products. These include addressing issues related to the gender inequities which are linked to the provision of HIV-prevention,
treatment and care for young girls and women. Effective programming for women and girls must therefore be based on
understanding the local, social and community contexts of the AIDS epidemic in the country, and adapting HIV strategies and
programmes accordingly. Such a framework therefore is needed not only to ensure optimal uptake of these new products by
women and girls but also to address sociocultural barriers to women’s and girls’ access to these products.
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Introduction
Two new microbicide products based on topical (vaginal)
application of antiretroviral drugs for HIV prevention  1%
tenofovir gel and the dapivirine intravaginal ring  are cur-
rently in late-stage clinical testing and results on their safety
and efficacy are expected to become available in early 2015.
To ensure that these products are able to reach women and
young girls most at risk of HIV acquisition, their launch must
be accompanied by WHO guidelines on the use of topical pre-
exposure prophylaxis (topical PrEP). These guidelines must be
evidence-based and integrate human rights standards and
principles with recommendations taking into account policy,
programmatic and community considerations. These guide-
lines are important to ensure that new topical PrEP products
are implemented in high HIV incidence countries and settings
in a manner that is equitable and effective. WHO recommen-
dations have a strong influence on policy, can accelerate
implementation in resource-limited settings and are neces-
sary for accessing funding from some donors. They contain
clinical, public health and policy recommendations about
health interventions, and provide information about what
policy makers, health-care providers or patients should do
[1]. WHO has adopted internationally recognized standards
and methods for guideline development [2] to ensure that
guidelines are unbiased and that the products or interven-
tions meet a public health need. The recommendations are
based on a comprehensive and objective assessment of the
available evidence and the process used to develop the
recommendations is clearly described. WHO guidelines are
complementary to regulatory review and approval. While
national regulatory authorities have the responsibility to
determine whether a product should be allowed onto the
market in their jurisdiction, WHO guidelines provide advice
for national programme managers and policy makers as they
decide whether and how a product should be used. This
advice addresses, for example, whether and how it should
be prioritized to certain segments of the population or risk
groups, and how to deliver the new product in an efficient
and cost-effective manner with due consideration to other
priority health interventions.
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Given that new topical PrEP products are designed to be
initiated by the woman herself and will likely be primarily
delivered in reproductive health settings, it is important to
ensure that national programmes are designed and services
delivered within a framework of comprehensive sexual and
reproductive health and human rights. Human rights stan-
dards, principles and treaties provide guarantees specifically
relating to access to contraceptives. In addition, they recom-
mend, among other actions, that states should ensure timely
and affordable access to good quality sexual and reproduc-
tive health information and services, including contraception,
which should be delivered in a way that ensures fully informed
decision-making, respects dignity, autonomy, privacy and con-
fidentiality, and is sensitive to individuals’ needs and perspec-
tives. These guarantees are essential prerequisites to ensure
women and girls are able to access and use the new HIV
prevention methods.
WHO has recently issued guidance on ensuring that human
rights are integrated into the provision of contraceptive infor-
mation and services with a total of 24 recommendations
on how this can be achieved [3]. Promotion and protection
of human rights of women and girls are at the centre of
this approach, including their right to have control over and
decide freely and responsibly on matters related to their
sexual and reproductive health, free of coercion, discrimina-
tion and violence. This requires governments to adopt and
accelerate the implementation of laws, policies and pro-
grammes which protect and enable the enjoyment of all
human rights and fundamental freedoms, including their
reproductive rights in accordance with the International Con-
ference on Population and Development (ICPD) Programme
of Action [4], the Beijing Declaration and Platform for Action
[5] and the 2004 WHO Global Reproductive Health Strategy
[6]. Human rights are guaranteed in international and regional
treaties, as well as in national constitutions and laws. They
include the right to non-discrimination; the right to life,
survival and development; the right to the highest attainable
standard of health; and the rights to education and to
information.
These rights have been applied by international, regional
and national authoritative human rights bodies  such as UN
treaty-monitoring bodies, international and regional courts,
and national courts  to a wide range of sexual and
reproductive health issues, including HIV, sexually transmitted
infections (STIs), and recently to the accessibility of contra-
ceptive information and services. This approach also reso-
nates with global health programmes such as the PEPFAR
Gender Strategy which recognizes that gender inequalities
increase women’s and girls’ vulnerability to HIV and must be
addressed in designing and implementing HIV programmes, in
particular the HIV prevention programmes [7]. The invest-
ment to develop new woman-initiated methods for HIV pre-
vention has been driven by the recognition that there remain
important gaps in HIV prevention, particularly for young
women in generalized HIV epidemic settings, who remain
at high risk of infection, even in clinical trial settings with
intensive HIV risk reduction interventions. This is well illu-
strated by the HIV incidence among women in the placebo
arms of recent randomized controlled trials of novel HIV
prevention methods  5.0 per 100 person years in the FEM-
PrEP trial of oral PrEP trial conducted in Kenya, South Africa
and Tanzania [8], 5.7 in the VOICE trial of oral and vaginal
products conducted in South Africa and Uganda [9], 5.9 in
the Phambili vaccine trial in South Africa [10] and 9.1 in the
CAPRISA 004 trial of 1% tenofovir gel [11]. While condoms
are highly effective in reducing the risk of HIV infection in
serodiscordant couples [12] and among sex workers [13], their
use and impact remains stubbornly low in sex between
regular partners [14,15].
Discussion
A significant challenge to designing and implementing
programmes to deliver new HIV prevention methods is to
ensure that they are made available to, and used by, women
at high risk of HIV infection who are not using existing
methods. Many such women visit family planning and other
reproductive health services to obtain contraceptive advice
and supplies, or to seek treatment for STIs. Thus, these family
planning and reproductive health services have a key role to
play in providing information on the new HIV prevention
methods, even if a woman can only obtain the products from
a limited number of facilities. Making the products available
to women who do not access family planning or other
reproductive health services will be a greater challenge and
innovative programmatic approaches must be developed.
Building upon existing human rights standards and princi-
ples, several issues are particularly relevant in the context of
provision of woman-initiated HIV prevention products. These
include, but are not limited to, improving quality of services
through:
1) integration of and/or linkages between reproductive
health and HIV services which provide topical HIV
prevention, condoms and contraceptive commodities,
supplies and equipment, covering a range of methods,
including emergency contraception.
2) providing evidence-based, comprehensive information,
education and counselling to ensure informed choice
with regard to contraception, and to prevention and
care for HIV and other STIs.
The ICPD Programme of Action recognizes that women and
adolescent girls, especially those who live in impoverished
and otherwise disadvantaged communities and circumstances,
disproportionately bear the greatest costs and consequences
of failure to promote and protect sexual and reproductive
health and reproductive rights. However, many women who
would benefit most from these new HIV prevention products
are young women and adolescents who, in many commu-
nities, have poor access to services. They may live in contexts
where health-care providers do not have the training or
the means to provide young people with age-appropriate
services, or choose not to do so based on their own biases.
Legal and policy barriers, such as parental consent require-
ments, can also inhibit girls’ access to services. Issues of con-
fidentiality, women’s empowerment and participation and
accountability are essential to ensure promotion and protec-
tion of sexual and reproductive health and human rights
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of women and girls. For instance, women’s privacy, including
confidentiality of medical and other personal information,
needs to be respected throughout the provision of HIV and
STI prevention and care, and contraceptive information and
services. For some women, using, or trying to use, one of
the new HIV prevention products may expose them to
violence, or exacerbate the risk of intimate partner violence.
The ICPD Programme of Action also obliges governments
to ensure availability of and access to the information,
comprehensive sexuality education, and quality sexual and
Table 1. Key operational and policy research priorities for provision of topical PrEP
Priority area Research elements
Define the core service package to deliver tenofovir gel and
dapivirine ring safely and appropriately in different service
delivery settings (family planning clinics, HIV testing sites,
sexual and reproductive health services)
 HIV testing and retesting models (including frequency, location and self-
testing or provider-led testing)
 Prescribing and resupply models (location of initial supply and refills,
frequency of product dispensing)
 Counselling approaches
 Whether and how to monitor for drug resistance in newly infected
product users
 Frequency and methods for measuring adherence
 Barriers to use (travel, time in clinic)
Determine how best to provide topical PrEP to
adolescents and young women
(aged 15 to 24)
 Clinical safety studies in women below age 18 years to allow labelling for
use in this age group
 Feasibility and acceptability of delivering tenofovir gel and dapivirine rings
to young women
 Willingness and ability to use the product
 How to offer topical PrEP without undermining condom use
 Young women’s beliefs about the products, risks and how these might
affect adherence
 Site-specific situation analyses to identify where young women go, or
would go, to access topical PrEP for HIV prevention
Support consistent product use  Tools to determine which factors influence use, and identify reasons for
non-use
 Examine factors at multiple levels that influence product use, and can be
complemented by objective measures of adherence
 Develop approaches that allow support to be tailored to the individual user
 Ongoing assessment of adherence to products known to be safe and effective
Develop provider training materials  Develop, test and adapt materials as experience in implementing
programmes and supporting users accumulate
 Draw on clinical trial documents and evidence as well as available training
materials from other sexual and reproductive health and HIV prevention
technologies
 Practical tools for screening potential users to be used by providers and
women to help identify those at high risk of HIV, those likely to adhere to
product use, and other approaches for defining users
Conduct policy analysis and synthesis to build an
enabling environment
 Synthesize evidence, outstanding questions and approaches to monitoring
and minimizing resistance to address policymaker concerns
 Synthesize evidence, outstanding questions and approaches to monitoring
and minimizing risk compensation to address policymaker concerns
 Identify the best strategies and approaches to demand creation
 Determine how best to anticipate and address social issues (partner
testing and disclosure, preventing and addressing intimate partner
violence, considerations for sex workers)
 Identify needed data to inform consistent approach and parameters for
modeling cost effectiveness, impact and other key outcomes
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reproductive health services necessary to ensure sexual and
reproductive health and enjoy human rights.
Results from the CAPRISA 004 trial announced in 2010
showed that 1% tenofovir gel used around the time of
intercourse reduced the risk of HIV infection by 39% among
women in KwaZulu-Natal [11] and the FACTS001 study of the
same product, currently underway in eight sites in South Africa,
is expected to announce preliminary results in early 2015
[16]. This is in contrast to the VOICE trial of daily gel use
which showed no reduction in HIV incidence when users
were instructed to use the product every day irrespective
of anticipated or actual sexual intercourse [9]. The failure to
show any protective effect was attributed to poor adherence
to daily product use. The product in a coitally dependent
regimen is not likely to be licensed for use for at least two
years, given the time necessary to collate data, prepare the
regulatory dossier, submit to national regulatory authorities
and allow in-depth regulatory review. It will be a further
one or two years before the product becomes more widely
available to women at high risk of HIV infection who choose
to use it. A similar process and timeframe is expected for
the second topical microbicide product in development, a
vaginal ring containing the antiretroviral dapivirine which is
currently in two parallel Phase 3 trials in Malawi, South Africa,
Uganda and Zimbabwe [17,18]. The intervening time from
the end of Phase 3 trials to product availability provides
an opportunity to implement operational research among
former trial participants, new users and/or communities that
have not been previously involved in the research. A care-
fully designed programme of operational research will inform
service delivery approaches to best make the products avail-
able and support women in their use.
In contrast, there was no opportunity to implement oper-
ational research and learn how to design access programmes
before oral PrEP was licensed in the United States in 2012.
In 2010, the iPrEx study showed that daily oral tenofovir
disoproxil fumarate and emtricitabine (TDF/FTC) reduced the
risk of HIV infection by 44% among men and transgender
women who have sex with men [19]. Additional studies
published in 2012 showed that TDF alone or TDF/FTC was
also effective in reducing HIV infection in heterosexual men
and women in known serodiscordant couples, injecting drug
users and other high HIV risk men and women [2022].
The combination TDF/FTC was approved for use in HIV
prevention by the US Food and Drug Administration and
WHO released programme guidance in July 2012 with
a provisional recommendation on use within the context
of demonstration projects for serodiscordant couples, and
men and transgender women who have sex with men [23].
The absence of programmatic experience or implementation
research on how to deliver oral PrEP to users prevented more
specific recommendations from being made at that time.
A wide array of introductory and demonstration projects on
oral PrEP are now being developed and implemented. These
demonstration projects will provide important information
over the next two years on acceptable and sustainable pro-
gramme design, how to reach men and women at risk of HIV
infection who wish to access and use oral PrEP and how to
retain them in a comprehensive combination HIV prevention
programme. However, the majority of the ongoing or planned
demonstration projects are in serodiscordant couples, sex
workers and men or transgender women who have sex with
men. Only 2 of the 26 oral PrEP demonstration projects listed
by AVAC in December 2013 involve women at risk of HIV
Table 2. Research phases and characteristics of operations research studies
Phase of research Settings/key characteristics Key outcomes
 Before product licensure
Open label extension of efficacy trials Efficacy trial sites
Participation limited to efficacy trial
participants
All are former trial participants and
successful prior users
Additional safety data to support licensure
Key questions to allow less restrictive labeling: e.g.
 Frequency of HIV testing, product resupply
 Adherence support models
 Alternative service delivery settings
Pilot introductory studies and operations
research (following safety and
effectiveness, prior to licensure)
New users
Can be in trial sites or other settings
Research requires ethical and regulatory
approvals and individual informed consent
Inform guidance and product labeling
Inform initial programme design (e.g. minimum
service package, efficient adherence support models,
feasible and sustainable service delivery models)
Extend to new user groups (e.g. extended age range,
relaxed eligibility criteria and extension to users
previously excluded due to minor contraindications)
 After product licensure
Demonstration projects/implementation
research
New users
Projects developed to inform programme
design
Research designed and conducted in the
context of ongoing programmes
Inform successful programme scale up and adaptation
Inform development of updated guidance as
experience with product delivery and use
accumulates
Address public health use of products
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infection who are neither sex workers nor in a stable, known
serodiscordant relationship [24]. It is these women at risk of
HIV infection who are likely to pioneer use of, and benefit
most from, topical PrEP.
In March 2014, WHO and CAPRISA convened a stakeholder
consultation to identify priority implementation research
on tenofovir gel and dapivirine ring to inform develop-
ment of WHO guidelines on the use of topical PrEP [25].
The consultation brought together a range of stakeholders
to determine what issues were most critical for WHO guide-
line development, and the research approaches and timing
where they can be addressed. Building on research questions
and information gaps identified at previous consultations con-
vened since the release of the CAPRISA 004 results, con-
sultation participants prioritized key operational and policy
research priorities for the provision of topical PrEP (Table 1).
In addition, stakeholders at the consultation noted that
programme implementation of tenofovir gel and dapivirine
ring could be addressed in each of the three phases of
research: 1) open label extensions of the ongoing clinical
trials; 2) pilot introductory studies and operational research
after confirmation of safety and efficacy, but before product
licensure; and 3) programmatic research following product
licensure (Table 2). The stakeholder consultation strongly
reaffirmed that implementation research and roll-out should
be prioritized in communities and countries that have hosted
clinical trials of topical PrEP and other HIV prevention trials
in women, including full support for open label extension
studies in the sites where trials of tenofovir gel and dapivirine
ring are ongoing.
Conclusions
Given the continued high rate of new infections among
women, especially young women in generalized HIV epi-
demics, it is critical to determine how best to ensure that
effective HIV prevention products, including topical PrEP, can
be delivered appropriately and sustainably. Given the gender
inequities that drive the need for women-initiated products,
WHO guidance on topical PrEP must not only build upon
relevant existing WHO guidelines but also be grounded in a
comprehensive sexual and reproductive health and human
rights framework. Such guidance will be highly influential in
determining how these products are provided, accelerating
programme uptake of new technologies in resource-limited
settings, and facilitating purchase and programme support by
international agencies and donors.
Timely design and implementation of a programme of
introductory and demonstration studies on topical PrEP will
ensure that the period between confirmation of safety and
efficacy and product licensure is best used. This period can
generate new knowledge on how to deliver the products to
users in an effective and sustainable manner, how to retain
users in prevention programmes, what mix of HIV prevention
methods can be effectively and efficiently delivered to-
gether, how to integrate with existing sexual and reproductive
health programmes and how to involve the community and
potential users in programme design, implementation and
monitoring.
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